Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Retina Institute of Hawaii100 enrolled

Overview

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

To determine mean change in visual acuity at 6 and 12 months

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Wet AMD

Interventions

LucentisDRUG

0.5mg Lucentis every four months

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age greater then and equal 50 years * Patients with active neovascular AMD * Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months * If the patient has bilateral disease and qualifies for the study, both eyes may be included Exclusion Criteria: * Subjects who meet any of the following criteria will be excluded from this study: * Pregnancy or lactation * Premenopausal women not using adequate contraception. * Participation in another simultaneous medical investigation

Locations (1)

Retina Institute of Hawaii

Honolulu, Hawaii, United States

Outcomes

Primary Outcomes

Mean change in visual acuity at 6 and 12 months

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.